The invention and advancement of in-silico studies not only provide a prodigious impact on discovering therapeutics in the most efficient means but also work as a bridge between synthetic and medicinal chemistry. The discovery and repurposing of multiple therapeutics to fight against SARS-CoV-2 in a very short period is it's great evidence to overcome the epidemic to a great extent. Since the rapid progression of the COVID-19 epidemic, a large number of studies and clinical trials are being performed around the globe. However, there have been a very limited number of drugs were identified which may act effectively against the novel coronavirus. The problem is attributed to the lack of knowledge about the complicated structures and detailed functions of the essential virus proteins and the rapidly mutating tendency of the SARS-CoV-2. The novel coronavirus belongs to the 'Coronaviridae' family, the largest family of RNA viruses consisting of long RNA strands as the genome. Thus, it exhibits a complex structure-activity relationship. At its core, SARS-CoV-2 is ensconced within a lipid bilayer envelope.